サイト内検索

登録済み会員ログイン




未登録の方はこちらから登録できます。
新規会員登録

連絡先

TEL．03-5812-5270
FAX．03-3831-0495
E-mail：info@spi-information.com

関連サイト・サービス

市場調査のご依頼、専門分野のイベント・フォーラムの開催などは シード・プランニングにて承っております。

シードプランニング

セキュリティについて

当サイトのコンテンツ利用時に送信される機密情報は、Verisign認証の元暗号化されて送信されます。

Non-Hodgkin’s Lymphoma (NHL) - Drug Pipeline Analysis and Market Forecasts to 2015

非ホジキンリンパ腫（NHL）：薬剤パイプライン分析と2015年までの市場予測

レポート概要

本レポートは、世界のNHL市場における不可欠なデータを提供しています。また、世界のNHL市場でのダイナミズムを形成し、かつ促進させる主要な傾向を特定します。そして、現在の市場勢力図や、既存リーダーの市場での地位に重要な変化をもたらすと予想される新たな企業についての洞察を提供します。さらに、世界のNHL市場におけるパイプライン製品について、貴重な見識を提供します。

■調査範囲

  • 2000〜2008年までの年間市場収益と2015年までの7年間の予測を提供します。
  • アメリカ、イギリス、イタリア、スペイン、ドイツ、フランス、日本の市場をカバーします。
  • さまざまなフェーズ、開発中の作用機序、および新たな動向について、パイプライン分析データを提供します。
  • 世界のNHL市場における現在および将来の市場競争を分析します。主要企業は、Genentech, Inc社、GSK社、Eli Lilly and Company社、Pfizer Inc社/ Wyeth社、Novartis AG社、Biogen Idec社。
  • 業界の促進因子、規制、および課題について洞察力のある論評を提供します。
  • 戦略的競合分析、市場特徴、アンメットニーズ、およびNHLの将来市場にかかわる事項についてカバーします。
  • GlobalData社の業界専門家のチームによる独自のデータベース、一次的および二次的研究、および社内の分析から、データと情報を提供します。

レポート詳細

目次

1 Table of contents
1.1 List of Tables
1.2 List of Figures

2 Non-Hodgkin's Lymphoma Market: Market Characterization
2.1 Overview
2.2 Non-Hodgkin's Lymphoma Market Size
2.3 Non-Hodgkin's Lymphoma Market Forecast and CAGR
2.4 Drivers and Barriers for Non-Hodgkin's Lymphoma Market
2.4.1 Drivers for Non-Hodgkin's Lymphoma Market
2.4.2 Barrier for Non-Hodgkin's Lymphoma Market
2.5 Opportunity and Unmet Need
2.6 Key Take Away

3 Non-Hodgkin's Lymphoma Market: Competitive Assessment
3.1 Overview
3.2 Strategic Competitor Assessment
3.3 Product Profile for the Major Marketed Products in the Non-Hodgkin's Lymphoma Market
3.3.1 Rituxan (MabThera)
3.3.2 Velcade®
3.3.3 Bexxar
3.3.4 Zevalin
3.3.5 Treanda
3.3.6 Campath (MabCampath or Campath-1H)
3.4 Recently Approved NHL Drugs for Non-Hodgkin's Lymphoma
3.4.1 Folotyn
3.4.2 Mozobil
3.5 Key Take Away

4 Non-Hodgkin's Lymphoma Market: Pipeline Assessment
4.1 Overview
4.2 Strategic Pipeline Assessment
4.2.1 Technology Trends Analytical Framework
4.3 Non-Hodgkin's Lymphoma Therapeutics – Promising Drugs under Clinical Development
4.4 Molecule Profile for Promising Drugs under Clinical Development
4.4.1 BiovaxID
4.4.2 Afinitor
4.4.3 Reviroc
4.4.4 Ontak
4.4.5 LY317615
4.5 Non-Hodgkin's Lymphoma Therapeutic Market – Clinical Pipeline by Mechanism of Action
4.6 Non-Hodgkin's Lymphoma Pipeline –Pipeline by Phases of Development
4.6.1 Non-Hodgkin's Lymphoma Monotherapies and Combination Therapies Pipeline– Phase III Clinical Studies
4.6.2 Non-Hodgkin's Lymphoma Monotherapies and Combination Therapies Pipeline – Phase II Clinical Trials
4.6.3 Non-Hodgkin's Lymphoma Monotherapies and Combination Therapies Pipeline – Phase I Clinical Studies
4.6.4 Non-Hodgkin's Lymphoma Monotherapies and Combination Therapies Pipeline– Preclinical Studies
4.7 Discontinued/ Suspended Drugs for Non-Hodgkin's Lymphoma
4.8 Key Take Away

5 Non-Hodgkin's Lymphoma Market: Implications for Future Market Competition

6 Non-Hodgkin's Lymphoma Market: Future Players in Non-Hodgkin's Lymphoma Market
6.1 Introduction
6.2 Genentech, Inc. (Roche)
6.2.1 Company Overview
6.2.2 Business Description
6.2.3 Company Pipeline
6.3 GlaxoSmithKline plc. (GSK)
6.3.1 Company Overview
6.3.2 Business Description
6.3.3 Company Pipeline
6.4 Immunomedics, Inc.
6.4.1 Company Overview
6.4.2 Business Description
6.4.3 Company Pipeline
6.5 Allos Therapeutics, Inc.
6.5.1 Company Overview
6.5.2 Business Description
6.5.3 Company Pipeline
6.6 Seattle Genetics, Inc.
6.6.1 Company Overview
6.6.2 Business Description
6.6.3 Company Pipeline
6.7 Eli Lilly and Company
6.7.1 Company Overview
6.7.2 Business Description
6.7.3 Company Pipeline
6.8 Pfizer Inc. (Wyeth)
6.8.1 Company Overview
6.8.2 Business Description
6.8.3 Company Pipeline
6.9 Novartis
6.9.1 Company Overview
6.9.2 Business Description
6.9.3 Company Pipeline
6.10 Biogen Idec
6.10.1 Company Overview
6.10.2 Business Description
6.10.3 Company Pipeline
6.11 Genzyme Corporation
6.11.1 Company Overview
6.11.2 Business Description
6.11.3 Company Pipeline

7 Non-Hodgkin's Lymphoma Market: Appendix
7.1 Definitions
7.2 Abbreviations
7.3 Research Methodology
7.3.1 Coverage
7.3.2 Secondary Research
7.3.3 Forecasting
7.3.4 Primary Research
7.3.5 Expert Panel validation
7.4 Contact Us
7.5 Disclaimer
7.6 Sources

List of Figures
Figure 1: Global Non-Hodgkin's Lymphoma Market Forecast ($m), 2000-2015
Figure 2: Opportunity and Unmet Need in the Non-Hodgkin's Lymphoma Market, 2010
Figure 3: Strategic Competitor Assessment, 2010
Figure 4: Technology Trends Analytic Framework – Non-Hodgkin's Lymphoma Market, 2010
Figure 5: Technology Trends Analytic Framework of the Rheumatoid Arthritis Pipeline – Description, 2010
Figure 6: Non-Hodgkin's Lymphoma Therapeutics Market – Clinical Pipeline by Mechanism of Action, 2010
Figure 7: Non-Hodgkin's Lymphoma Pipeline by Phase of Clinical Development, 2010
Figure 8: Implications for Future Market Competition in Non-Hodgkin's Lymphoma, 2010
Figure 9: Non-Hodgkin's Lymphoma Therapeutics Market – Clinical Pipeline by Company, 2010
Figure 10: Non-Hodgkin's Lymphoma Market, Global–Companies Having Highest Number of Molecules in Pipeline, 2010
Figure 11: GlobalData Methodology
Figure 12: GlobalData Market Forecasting Model

List of Tables
Table 1: Non-Hodgkin's Lymphoma Market, Global, Revenues ($m), 2000–2008
Table 2: Non-Hodgkin's Lymphoma Market, Global, Revenues ($m), 2008–2015
Table 3: Major Marketed Products Comparison in Non-Hodgkin's Lymphoma Market, 2010
Table 4: Non-Hodgkin's Lymphoma Therapeutics – Most Promising Drugs in Clinical Development, 2010
Table 5: Non-Hodgkin's Lymphoma Monotherapies Pipeline – Phase III Clinical Studies, 2010
Table 6: Non-Hodgkin's Lymphoma Combination Therapeutics Pipeline– Phase III Clinical Studies, 2010
Table 7: Non-Hodgkin's Lymphoma Monotherapies Pipeline – Phase II Clinical Studies, 2010
Table 8: Non-Hodgkin's Lymphoma Combination Therapies Pipeline– Phase II Clinical Studies, 2010
Table 9: Non-Hodgkin's Lymphoma Monotherapies Pipeline – Phase I Clinical Studies, 2010
Table 10: Non-Hodgkin's Lymphoma Combination Therapies Pipeline – Phase I Clinical Studies, 2010
Table 11: Non-Hodgkin's Lymphoma Mono Therapeutics and Combination Therapeutics Pipeline– Preclinical Studies, 2010
Table 12: List of Discontinued/Suspended Drugs for Non-Hodgkin's Lymphoma, 2010
Table 13: F. Hoffmann-La Roche Ltd.- Oncology Pipeline Products, 2010
Table 14: F. Hoffmann-La Roche Ltd. - Non-Hodgkin's Lymphoma Pipeline Products, 2010
Table 15: Genentech Inc. – Oncology Product Pipeline, 2010
Table 16: Genentech Inc. – Non-Hodgkin's Lymphoma Product Pipeline, 2010
Table 17: GlaxoSmithKline plc. – Oncology Product Pipeline, 2010
Table 18: GlaxoSmithKline plc. – Non-Hodgkin's Lymphoma Product Pipeline, 2010
Table 19: Immunomedics, Inc. – Oncology Product Pipeline, 2010
Table 20: Immunomedics, Inc. – Non-Hodgkin's Lymphoma Product Pipeline, 2010
Table 21: Allos Therapeutics, Inc – Oncology Product Pipeline, 2010
Table 22: Allos Therapeutics, Inc – Non-Hodgkin's Lymphoma Product Pipeline, 2010
Table 23: Seattle Genetics, Inc. – Oncology Product Pipeline, 2010
Table 24: Seattle Genetics, Inc. – Non-Hodgkin's Lymphoma Product Pipeline, 2010
Table 25: Eli Lilly and Company – Oncology Product Pipeline, 2010
Table 26: Eli Lilly and Company – Non-Hodgkin's Lymphoma Product Pipeline, 2010
Table 27: Pfizer Inc. (Wyeth) – Oncology Product Pipeline, 2010
Table 28: Pfizer Inc. (Wyeth) – Non-Hodgkin's Lymphoma Product Pipeline, 2010
Table 29: Novartis – Oncology Product Pipeline, 2010
Table 30: Novartis – Non-Hodgkin's Lymphoma Product Pipeline, 2010
Table 31: Biogen Idec – Oncology Product pipeline, 2010
Table 32: Biogen Idec – Non-Hodgkin's Lymphoma Product pipeline, 2010
Table 33: Genzyme Corporation – Oncology Product pipeline, 2010
Table 34: Genzyme Corporation – Non-Hodgkin's Lymphoma Product pipeline, 2010

発刊日

2010/01/14

体裁

PDF / 84ページ

販売価格

2,000USD

発行

GlobalData

備考

※ご請求は、お申込日のTTSレートで円換算し、消費税を加えた金額になります。
※本レポートは、英文です。PDF(電子媒体)での納品となります。
※本レポートは取り寄せとなりますので、申し込みからお届けまで、多少時間が掛かる場合がございます。

関連カテゴリ

疾病別治療・領域別治療

購入・お問い合わせ

このレポートを購入

詳細を問い合わせる

PAGE